Methods of treating hepatitis delta virus infection
Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.
1. A method of treating a hepatitis delta virus (HDV) infection in a human patient with an HDV infection, comprising:
administering to the human patient a therapeutically effective amount of an amorphous co-precipitate comprising:
lonafarnib or a pharmaceutically acceptable salt thereof;
ritonavir or a pharmaceutically acceptable salt thereof; and
a co-polymer;
wherein the amorphous co-precipitate is substantially free of crystalline forms.
2. The method of claim 1 , wherein the amorphous co-precipitate is orally administered.
3. The method of claim 1 , wherein the amorphous co-precipitate is administered once daily or twice daily.
4. The method of claim 1 , wherein the amorphous co-precipitate is administered at a daily dose of lonafarnib of 50 mg to 200 mg.
5. The method of claim 1 , wherein the human patient is treated with the amorphous co-precipitate for at least 30 days, at least 60 days, at least 90 days, at least 120 days, at least 150 days, or at least 180 days.
6. The method of claim 1 , wherein treatment of the human patient results in an HDV viral load of less than 3 log HDV RNA copies/mL serum.
7. The method of claim 1 , further comprising administering to the human patient an interferon.
8. The method of claim 7 , wherein the interferon comprises an interferon-alpha and/or an interferon-lambda.
9. The method of claim 1 , further comprising administering to the human patient a gastrointestinal modifying agent.
10. The method of claim 1 , wherein the co-polymer is selected from the group consisting of polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hypromellose phthalate, polyvinylpyrrolidone-vinylacetate copolymer, hypromellose-acetate-succinate, and mixtures thereof.
11. The method of claim 1 , wherein the lonafarnib or pharmaceutically acceptable salt thereof and the ritonavir or pharmaceutically acceptable salt thereof are present in a ratio of 1:1 (w/w).
12. The method of claim 1 , wherein the lonafarnib or pharmaceutically acceptable salt thereof, the ritonavir or pharmaceutically acceptable salt thereof, and the co-polymer are present in a ratio of 1:1:2 (w/w), 1:2:3 (w/w), or 1:1:5 (w/w).
13. The method of claim 1 , further comprising a solvent selected from the group consisting of dichloromethane, chloroform, isopropyl alcohol, methanol, ethanol, acetone, ethyl methyl ketone, methyl isobutyl ketone, DMSO, water, and mixtures thereof.
14. A method of treating a hepatitis delta virus (HDV) infection in a human patient with an HDV infection, comprising:
administering to the human patient a therapeutically effective amount of a unit dosage form comprising an amorphous co-precipitate comprising:
lonafarnib or a pharmaceutically acceptable salt thereof;
ritonavir or a pharmaceutically acceptable salt thereof; and
a co-polymer;
wherein the amorphous co-precipitate is substantially free of crystalline forms; and
wherein the unit dosage form comprises lonafarnib or a pharmaceutically acceptable salt thereof in an amount of 25 mg, 50 mg, 75 mg, or 100 mg and ritonavir or a pharmaceutically acceptable salt thereof in an amount of 50 mg, 75 mg, or 100 mg.
15. The method of claim 14 , wherein the unit dosage form comprises 25 mg lonafarnib and 100 mg ritonavir.
16. The method of claim 14 , wherein the amorphous co-precipitate is orally administered.
17. The method of claim 14 , wherein the amorphous co-precipitate is administered once daily or twice daily.
18. The method of claim 14 , wherein the amorphous co-precipitate is administered at a daily dose of lonafarnib of 50 mg to 200 mg.
19. The method of claim 14 , wherein the human patient is treated with the amorphous co-precipitate for at least 30 days, at least 60 days, at least 90 days, at least 120 days, at least 150 days, or at least 180 days.
20. The method of claim 14 , wherein treatment of the human patient results in an HDV viral load of less than 3 log HDV RNA copies/mL serum.
21. The method of claim 14 , wherein the unit dosage form further comprises a pharmaceutically acceptable excipient, a diluent, a carrier, and/or an adjuvant.
22. The method of claim 14 , wherein the unit dosage form is a solid formulation selected from the group consisting of a tablet, caplet, gelcap, and a capsule.
23. The method of claim 14 , wherein the unit dosage form is a delayed release formulation or an enteric release formulation.